Lead by proven industry experience, Marvel is at the forefront of modern science.
We are a life sciences company whose primary focus is the discovery and the development of a synthetic derivative compound of a known proven drug. Our business model capitalizes on significantly lower cost, less time and a lower risk profile to bring a drug asset to commercialization faster than the traditional long-term biotech model.
The Company has been specifically focused on the discovery of new chemical entities that inhibits the A2a adenosine receptor. The A2a receptor is a target for a number of diseases representing areas of significant unmet medical needs, each with multi-billion dollar potential, and with fundamentally no competitors.
Our drug assets are targeted for the treatment of large and growing markets associated with a predominantly aging population.
The Company is targeting specifically
that have not been treated with
Currently no approved therapies
Pursuing as an adjunctive
Shares Outstanding : 32,586,231
Insider Ownership : 12,525,098 (38.4%)
Warrant coverage : 10,071,533
Stock options granted : 2,825,000
Marvel Biosciences Completes a Critical Manufacturing Milestone Required to Enter Phase 1 Human Trials Targeting Alzheimer’s Disease and Depression
Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company“ or “Marvel“), is pleased to announce that it has successfully completed a multi-kilogram scale run under current good manufacturing practices...
Marvel Biosciences Successfully Completes its Short Term Dose Ranging Study in Rats and Dogs for MB-204
Marvel Biosciences Corp. (TSV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company“ or “Marvel“), is pleased to announce that it has successfully completed its dose-ranging toxicology studies in rats and dogs, for its lead drug...
Marvel Biosciences Corp.
Suite 420, 505 8th Avenue S.W.
Calgary, Alberta T2P 1G2
Marvel Biosciences Corp. (the “Company”) is a life sciences company whose primary focus is the discovery and the development of a synthetic derivative compound of a known proven drug.